Literature DB >> 26314781

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

B Eichhorst1, T Robak2, E Montserrat3, P Ghia4, P Hillmen5, M Hallek6, C Buske7.   

Abstract

Entities:  

Mesh:

Year:  2015        PMID: 26314781     DOI: 10.1093/annonc/mdv303

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  97 in total

Review 1.  EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia.

Authors:  Julio Delgado; Filip Josephson; Jorge Camarero; Blanca Garcia-Ochoa; Lucia Lopez-Anglada; Carolina Prieto-Fernandez; Paula B van Hennik; Irene Papadouli; Christian Gisselbrecht; Harald Enzmann; Francesco Pignatti
Journal:  Oncologist       Date:  2021-02-10

2.  Ibrutinib in the real world patient: many lights and some shades.

Authors:  Paolo Ghia; Antonio Cuneo
Journal:  Haematologica       Date:  2016-12       Impact factor: 9.941

3.  Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.

Authors:  Anton W Langerak; Matthias Ritgen; Valentin Goede; Sandra Robrecht; Jasmin Bahlo; Kirsten Fischer; Michael Steurer; Marek Trněný; Stephen P Mulligan; Ulrich J M Mey; Kerstin Trunzer; Günter Fingerle-Rowson; Kathryn Humphrey; Stephan Stilgenbauer; Sebastian Böttcher; Monika Brüggemann; Michael Hallek; Michael Kneba; Jacques J M van Dongen
Journal:  Blood       Date:  2018-11-19       Impact factor: 22.113

Review 4.  Current Treatment of Chronic Lymphocytic Leukemia.

Authors:  Krzysztof Jamroziak; Bartosz Puła; Jan Walewski
Journal:  Curr Treat Options Oncol       Date:  2017-01

Review 5.  Chronic lymphocytic leukemia therapy: new targeted therapies on the way.

Authors:  Candida Vitale; Jan A Burger
Journal:  Expert Opin Pharmacother       Date:  2016-04-12       Impact factor: 3.889

6.  The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites.

Authors:  Anthony Mato; Chadi Nabhan; Nicole Lamanna; Neil E Kay; David L Grinblatt; Christopher R Flowers; Charles M Farber; Matthew S Davids; Arlene S Swern; Kristen Sullivan; E Dawn Flick; Sarah M Gressett Ussery; Mecide Gharibo; Pavel Kiselev; Jeff P Sharman
Journal:  Blood Adv       Date:  2020-04-14

7.  Examining the medical resource utilization and costs of relapsed and refractory chronic lymphocytic leukemia in Ontario.

Authors:  S Hassan; S J Seung; M C Cheung; G Fraser; B Kuriakose; C Trambitas; N Mittmann
Journal:  Curr Oncol       Date:  2017-02-27       Impact factor: 3.677

Review 8.  The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment.

Authors:  Gianluca Gaidano; Davide Rossi
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

9.  Elevated absolute NK cell counts in peripheral blood predict good prognosis in chronic lymphocytic leukemia.

Authors:  Wen-Ting Wang; Hua-Yuan Zhu; Yu-Jie Wu; Yi Xia; Jia-Zhu Wu; Wei Wu; Jin-Hua Liang; Li Wang; Lei Fan; Jian-Yong Li; Wei Xu
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-03       Impact factor: 4.553

Review 10.  Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia.

Authors:  Lesley J Scott
Journal:  Target Oncol       Date:  2019-10       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.